The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors

Heather Nesbitt, Jenny Worthington, Rachel J. Errington, Laurence H. Patterson, Paul J. Smith, Stephanie McKeown, Declan McKenna

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences